Proceedings: CB 154 (2-bromo-alpha-ergokryptine, bromocriptin), a potential anti-Parkinson agent.
D000818:Animals; D000978:Antiparkinson Agents / Q000494:pharmacology*; D001058:Apomorphine / Q000494:pharmacology; D001522:Behavior, Animal / Q000187:drug effects*; D001921:Brain / Q000187:drug effects*; D001966:Bromine / Q000494:pharmacology; D002375:Catalepsy / Q000139:chemically induced; D003913:Dextroamphetamine / Q000494:pharmacology; D004295:Dihydroxyphenylalanine / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004876:Ergot Alkaloids / Q000494:pharmacology*; D006801:Humans; D006892:Hydroxydopamines / Q000494:pharmacology; D051379:Mice; D051381:Rats; D012110:Reserpine / Q000037:antagonists & inhibitors / Q000494:pharmacology; D013239:Stereotyped Behavior / Q000187:drug effects; D013378:Substantia Nigra / Q000502:physiology; D013997:Time Factors
D000978:Antiparkinson Agents; D004876:Ergot Alkaloids; D006892:Hydroxydopamines; D004295:Dihydroxyphenylalanine; D012110:Reserpine; D001058:Apomorphine; D001966:Bromine; D003913:Dextroamphetamine